令人失望的是,事情并没有像他们设想的那样发展。生物技术公司只有一些点滴的成果,没有产生什么大的成果。徳平厚博士指出,自2007年以来,这个领域是私募股份市场上表现最差的领域之一。他希望改变这个局面。而研制抗癌新药的科技看来正处于幸运期。例如,2011年8月,美国批准了一种名为vemurafenib的新药,它可以把最恶性的癌症之一黑色素瘤病人的生命延长数月。这种药的效力是如此显著,以致一些人把它称为“拉扎罗斯”—— 那个被耶稣起死回生的麻风病人的名字。
Crucially for Dr DePinho's project, the development of vemurafenib was stimulated by the identification of a mutated gene often present in melanomas. He and others like him hope that the cancer-genome consortium will throw up dozens of similar genes, and that they, too, will prove tractable targets for drug development.
对徳平厚博士很有意义的是,vemurafenib的研发正是由于辨识了经常出现在黑色素瘤中的一种突变基因所推动的。徳平厚和同行们希望癌症基因图谱研究联盟能够发现几十种类似的基因,从而能够为新药研发提供可控的目标。
Of course, if Dr DePinho had a penny for every time a "cure for cancer" headline proved premature, he wouldn't need munificent donors. But if his bets on the science and on adopting business methods pay off, the drug industry and millions of patients will benefit. That would be one benign sort of metastasis.
【未来目标 攻克五种癌症】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15